Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 6/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15183144 | 0.93 | KDM4E (0.52) | HTR3AROCK1KDM4ENPSR1CNR1 | |
| SCHEMBL15605576 | 0.85 | KDM4E (0.51) | ROCK1KDM4ENPSR1CNR1CNR2 | |
| SCHEMBL10182574 | 0.83 | ROCK1 (0.49) | HTR3AROCK1KDM4ENPSR1HPGD | |
| SCHEMBL10182068 | 0.81 | ROCK1 (0.47) | HTR3AROCK1KDM4ENPSR1HPGD | |
| SCHEMBL14955577 | 0.81 | ROCK1 (0.53) | ROCK1KDM4ENPSR1HPGDPTK2B | |
| SCHEMBL10183283 | 0.79 | HDAC3 (0.52) | HTR3AROCK1KDM4ENPSR1HPGD | |
| SCHEMBL14956087 | 0.78 | ROCK1 (0.50) | ROCK1KDM4ENPSR1HPGDPTK2B | |
| SCHEMBL570538 | 0.77 | ROCK1 (0.44) | HTR3AROCK1KDM4ENPSR1HPGD | |
| SCHEMBL10182441 | 0.74 | HDAC1 (0.46) | HTR3AROCK1KDM4ENPSR1HPGD | |
| SCHEMBL10183958 | 0.74 | HDAC1 (0.46) | HTR3AROCK1KDM4ENPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | HTR3A 2298/4885ROCK1 3994/4885KDM4E 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.